Welcome to our dedicated page for Bodhi Tree Biotechnology SEC filings (Ticker: BDTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bodhi Tree Biotechnology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bodhi Tree Biotechnology's regulatory disclosures and financial reporting.
Bodhi Tree Biotechnology Inc. reported minimal but growing operations for the quarter and nine months ended June 30, 2026. Revenue for the nine-month period was $25,000, up from $5,000 a year earlier, with a net loss of $105,338 versus $138,979 in the prior-year period. For the quarter, revenue was $10,000 and the net loss was $23,194.
Cash declined sharply to $3,986 at June 30, 2026 from $109,404 at September 30, 2025, driven by $105,418 of net cash used in operating activities. Total assets were $18,323, with no debt and an accumulated deficit of $316,957. A majority shareholder has provided a written commitment to fund working capital through unsecured loans, which management believes alleviates substantial doubt about continued operations under the going concern framework.
The company remains pre-revenue scale, with highly concentrated sales among a few customers and no cost of revenues recognized. During the quarter, its common stock was approved for quotation on the OTCQB Venture Market, and subsequent to quarter-end it signed a $161,491 product sampling and trial production contract. Management disclosed material weaknesses in internal control over financial reporting, citing limited U.S. GAAP expertise and lack of segregation of duties.
Bodhi Tree Biotechnology Inc. reported a small but growing consulting business with continued losses for the quarter and six months ended March 31, 2026. Revenue for the six-month period was $15,000, up from $5,000 a year earlier, all from a single individual customer. General and administrative expenses were $95,883, down from $121,956, reflecting mainly professional fees and overhead.
The company recorded a six-month net loss of $82,144, an improvement from a $118,205 loss in the prior-year period, and used $86,654 of cash in operating activities. Cash declined to $22,750 and total assets to $40,517 as of March 31, 2026, while liabilities remained minimal at $3,500 of accrued expenses. Stockholders’ equity fell to $37,017.
Bodhi Tree has 25,441,042 common shares outstanding and relies on a highly concentrated revenue base. Management plans to fund operations through securities offerings or other financing. During the quarter, its common stock was approved for quotation on the OTCQB Venture Market. Management also reported material weaknesses in internal control over financial reporting, citing limited US GAAP knowledge and lack of segregation of duties.
Bodhi Tree Biotechnology Inc. reported a net loss of $52,948 for the three months ended December 31, 2025, compared with a $64,777 loss a year earlier. The company generated no revenue in the quarter, versus $5,000 in the prior-year period, as it builds its vegetarian menu and diet consulting business.
Cash declined to $47,366 from $109,404 at September 30, 2025, with total assets of $69,713 and stockholders’ equity of $66,213. Accumulated deficit reached $264,567, and operations were funded entirely by existing capital.
Management disclosed material weaknesses in internal control over financial reporting, citing limited U.S. GAAP expertise and insufficient segregation of duties. During the quarter, the company’s application to have its common stock quoted on the OTCQB Venture Market was approved, and certain share legends were removed to increase public float.
Bodhi Tree Biotechnology Inc., an early-stage vegetarian menu design and diet consulting company based in Danville, California, reported a small consulting business with limited operations in its annual report for the year ended September 30, 2025. Service revenue was $17,000, down from $35,000 for the prior period from inception to September 30, 2024, while general and administrative expenses rose to $164,618. The company recorded a net loss of $149,666 versus $61,953 previously, reflecting professional and overhead costs outpacing revenue.
As of September 30, 2025, Bodhi Tree held $109,404 in cash, total assets of $119,161, no liabilities, and stockholders’ equity of $119,161. There were 25,441,042 common shares outstanding as of both September 30 and December 29, 2025. The business has no full-time employees beyond executives, subleases a small office for $900 per month, owns two U.S. trademarks, and highlights numerous risks including limited operating history, dependence on key management, financing needs, competition, thin trading and penny-stock constraints.